Chinese Academy of Medical Sciences
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Private, Subsidiary
- Established
- 2004-07-08
- Employees
- -
- Market Cap
- -
Effects of Adjuvant Endocrine Therapy With Aromatase Inhibitors on the Postoperative Lipid Levels in Postmenopausal Breast Cancer Patients
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2016-05-06
- Last Posted Date
- 2019-05-13
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 500
- Registration Number
- NCT02765373
- Locations
- 🇨🇳
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
Optimizing the Strategy for Preoperative Chemotherapy in Locally Advanced Gastric/Gastroesophageal Cancer
Phase 2
Completed
- Conditions
- Gastric Cancer
- Interventions
- First Posted Date
- 2016-04-01
- Last Posted Date
- 2022-08-17
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 180
- Registration Number
- NCT02725424
- Locations
- 🇨🇳
Chinese Academy of Medical Sciences, Beijing, Beijing, China
Hypofractionated vs. Conventionally Fractionated Concurrent CRT for LD-SCLC
Phase 3
- Conditions
- Carcinoma, Small CellLung Neoplasms
- Interventions
- Radiation: hypofractionated concurrent chemoradiotherapyRadiation: conventionally fractionated concurrent chemoradiotherapy
- First Posted Date
- 2016-02-23
- Last Posted Date
- 2018-01-02
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 860
- Registration Number
- NCT02688036
- Locations
- 🇨🇳
Cancer Insititute and Hosiptal of Chinese Academy of Medical Sciences, Beijing, China
Neoadjuvant Triplet Chemotherapy Regimen in Patients With Resectable Colorectal Cancer
Phase 2
- Conditions
- Colorectal Cancer
- Interventions
- Drug: oxaliplatin;irinotecan;leucovorin;5-fluorouracil;capecitabine;S-1
- First Posted Date
- 2016-02-23
- Last Posted Date
- 2016-02-23
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 50
- Registration Number
- NCT02688023
- Locations
- 🇨🇳
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
Comparable Study of Different Thoracic Radiotherapy Regimens for Extensive Stage Small Cell Lung Cancer
Not Applicable
- Conditions
- Carcinoma, Small CellLung Neoplasms
- Interventions
- Radiation: high-dose TRTRadiation: standard-dose TRT
- First Posted Date
- 2016-02-05
- Last Posted Date
- 2019-04-04
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 186
- Registration Number
- NCT02675088
- Locations
- 🇨🇳
Cancer Insititute and Hosiptal of Chinese Academy of Medical Sciences, Beijing, Beijing, China
🇨🇳Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Stereotactic Radiotherapy Plus Temozolomide for Refractory Brain Metastases
Phase 2
Completed
- Conditions
- Brain Metastases
- Interventions
- Radiation: Fractionated Stereotactic Radiotherapy
- First Posted Date
- 2016-01-13
- Last Posted Date
- 2017-06-06
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 65
- Registration Number
- NCT02654106
- Locations
- 🇨🇳
Chinese Academy of Medical Sciences, Beijing, Beijing, China
A Randomized Phase III Study of Adjuvant Chemotherapy With or Without Chemo-radiotherapy in Patients With Local Advanced Gastric Cancer After D2 Resection.
Phase 3
- Conditions
- Gastric Cancer
- Interventions
- Drug: Adjuvant chemotherapy for active comparator groupRadiation: Adjuvant Concurrent Chemo-radiotherapyDrug: Adjuvant chemotherapy for experimental group
- First Posted Date
- 2016-01-07
- Last Posted Date
- 2016-01-07
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 588
- Registration Number
- NCT02648841
- Locations
- 🇨🇳
Cancer Hospital, Chinese academy of medical sciences, Bejing, Beijing, China
Fulvestrant 500mg With Exemestane Endocrine Therapy for Postmenopausal Advanced Breast Cancer Patients
- First Posted Date
- 2016-01-06
- Last Posted Date
- 2017-01-02
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 148
- Registration Number
- NCT02646735
- Locations
- 🇨🇳
National Cancer Institute, Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
Zoledronic Acid as Adjuvant Treatment of Triple-negative Breast Cancer
- First Posted Date
- 2015-11-03
- Last Posted Date
- 2015-11-03
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 430
- Registration Number
- NCT02595138
Trial of IPGDP Regimen Chemotherapy in Patients With Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type
Phase 2
- Conditions
- Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type
- Interventions
- Other: chemotherapy followed by radiotherapyOther: radiotherapy followed by chemotherapyDrug: IPGDP regimen chemotherapy
- First Posted Date
- 2015-09-25
- Last Posted Date
- 2018-01-03
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Registration Number
- NCT02560441
- Locations
- 🇨🇳
People's Hospital of Guangxi, Nanning, China
🇨🇳Fourth Hospital of Hebei Medical University, Shijiazhuang, China
🇨🇳Shanxi Dayi Hospital, Taiyuan, China
© Copyright 2025. All Rights Reserved by MedPath